Regeneron Pharmaceuticals: EYLEA Franchise, Dupixent Immunology, and Drug Pipeline

Monoclonal antibody production in the laboratory. Regeneron's VelociSuite technology platform enables rapid discovery and development of fully human monoclonal antibodies used across its product portfolio.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is a biotechnology company headquartered in Tarrytown, New York, with approximately $14.2 billion in total revenue (FY2024) and $14.3 billion in FY2025. Founded in 1988 by Leonard Schleifer and George Yancopoulos, Regeneron built its competitive advantage on proprietary antibody discovery technology and has grown into one of the world's largest independent biotech companies.

This article explains Regeneron's business model, key product franchises, technology platform, pipeline strategy, and key risks in plain English — without offering investment advice.

What Regeneron Actually Does

Regeneron discovers, develops, manufactures, and commercializes medicines using its proprietary VelociSuite technology platform. The company specializes in fully human monoclonal antibodies and operates across multiple therapeutic areas:

• Ophthalmology (EYLEA/EYLEA HD) — anti-VEGF therapies for retinal diseases including wet age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO)
• Immunology/Inflammation (Dupixent) — anti-IL-4/IL-13 antibody for type 2 inflammatory diseases, developed and commercialized with Sanofi. The world's leading medicine in this class.
• Oncology (Libtayo) — anti-PD-1 checkpoint inhibitor for various cancers including cutaneous squamous cell carcinoma and non-small cell lung cancer
• Rare diseases — Evkeeza (evinacumab) for homozygous familial hypercholesterolemia, Inmazeb for Ebola
• Pipeline areas — obesity, allergic conditions, hematology, gene therapy, bispecific antibodies

Regeneron employs over 15,400 people globally with offices in 12 countries. The company manufactures its own products at facilities in New York and Ireland, with planned investments exceeding $7 billion in U.S. infrastructure.

Revenue Structure (FY2024 / FY2025)

Key financial metrics:

• FY2024 total revenue: $14.20 billion (8% YoY growth; 10% excluding Ronapreve)
• FY2025 total revenue: $14.3 billion (1% growth — impacted by EYLEA biosimilar competition)
• Dupixent global net sales (recorded by Sanofi): $17.8 billion in FY2025 (26% growth). Regeneron receives ~50% of collaboration profits.
• EYLEA HD U.S. net sales: $1.6 billion in FY2025 (36% growth)
• Total EYLEA HD + EYLEA U.S. net sales: $4.4 billion in FY2025 (27% decline due to biosimilar erosion of legacy EYLEA)
• Libtayo global net sales: exceeded $1 billion in FY2024 (26% growth in Q3 2025)
• FY2025 GAAP EPS: ~$35 (Q4 2025 GAAP EPS $7.86)
• Initiated first quarterly dividend in 2025 — new capital return alongside buybacks
• Share repurchase capacity: ~$4.5 billion

The EYLEA Franchise — Ophthalmology Leadership

EYLEA (aflibercept) is an anti-VEGF injection used to treat retinal diseases where abnormal blood vessel growth or leakage damages vision. It has been one of the best-selling ophthalmology drugs globally since its launch in 2011.

• EYLEA (aflibercept 2 mg) — the original product, administered every 4–8 weeks by intravitreal injection. Approved for wet AMD, DME, diabetic retinopathy, and RVO. Now facing biosimilar competition as patents expire.
• EYLEA HD (aflibercept 8 mg) — next-generation higher-dose formulation approved 2023. Enables extended dosing intervals (up to 12–16 weeks between injections) while maintaining efficacy. Designed to retain patients transitioning from legacy EYLEA.
• Biosimilar challenge — multiple aflibercept biosimilars launched in 2024–2025, eroding legacy EYLEA volume. Total EYLEA franchise U.S. net sales declined 27% in FY2025. EYLEA HD is growing (36% in FY2025) but not fully offsetting legacy decline.
• FDA expansion — EYLEA HD approved for RVO in 2025 and for monthly dosing flexibility across all approved indications. Pre-filled syringe formulation under FDA review.

The EYLEA franchise remains Regeneron's largest directly-recorded revenue source, but its trajectory depends on how quickly EYLEA HD can capture share from both legacy EYLEA and biosimilar alternatives.

Dupixent — The Immunology/Inflammation Powerhouse

Dupixent (dupilumab) is a fully human monoclonal antibody that blocks interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling — key drivers of type 2 inflammation. Developed and commercialized through a collaboration with Sanofi, Dupixent is the world's leading targeted medicine for type 2 inflammatory diseases.

• Global net sales: $17.8 billion in FY2025 (26% growth). Recorded by Sanofi; Regeneron shares ~50% of collaboration profits.
• Approved indications — atopic dermatitis (adults and children 6 months+), asthma (moderate-to-severe eosinophilic/OCS-dependent), chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, COPD (Japan), chronic spontaneous urticaria (EU), bullous pemphigoid (US)
• Patient reach — treating over 850,000 patients globally as of 2024, with continued expansion into new indications and geographies
• Growth drivers — new indications (CSU, COPD, food allergy under study), geographic expansion, pediatric extensions, and increasing diagnosis rates for type 2 inflammatory conditions
• Collaboration economics — Sanofi records all Dupixent sales and shares profits with Regeneron. Regeneron also receives milestone payments and royalties on certain territories.

Oncology: Libtayo and Next-Generation Programs

• Libtayo (cemiplimab) — anti-PD-1 checkpoint inhibitor. Exceeded $1 billion in annual net sales in FY2024. Approved for advanced cutaneous squamous cell carcinoma (CSCC), basal cell carcinoma, non-small cell lung cancer (first-line), and adjuvant high-risk CSCC (FDA and EC approved 2025).
• Bispecific antibodies — Regeneron is developing bispecific antibodies that simultaneously bind two targets. Lynozyfic (linvoseltamab) approved in EU for relapsed/refractory multiple myeloma (2025).
• Costimulatory bispecifics — next-generation oncology programs combining checkpoint blockade with T-cell costimulation for enhanced anti-tumor immunity.
• Combination strategies — Libtayo combined with other agents in various tumor types under clinical investigation.

Pipeline and R&D

Regeneron invests heavily in R&D and maintains one of the broadest pipelines in biotech. Key programs:

• Obesity — trevogrumab (anti-myostatin) + Dupixent combination and other approaches targeting muscle preservation during weight loss. Multiple Phase 2 programs.
• Itepekimab — anti-IL-33 antibody for asthma and COPD in patients without type 2 inflammation (complementing Dupixent's type 2 focus)
• Fianlimab — anti-LAG-3 antibody combined with Libtayo for melanoma and other cancers. Phase 3.
• Gene therapy — first gene therapy approved by FDA in 2026 for profound hearing loss. Additional programs in development.
• Rare disease expansion — Evkeeza for broader hypercholesterolemia populations; new targets in hematology and metabolic disease
• Next-generation ophthalmology — longer-acting anti-VEGF approaches and combination therapies beyond EYLEA HD

VelociSuite Technology Platform

Regeneron's core competitive advantage is its proprietary VelociSuite technology platform for drug discovery:

• VelocImmune — genetically engineered mice with humanized immune systems that produce fully human antibodies in response to any antigen. Eliminates the need to "humanize" mouse antibodies, reducing development time and immunogenicity risk.
• VelociGene — high-throughput gene targeting technology for creating genetically modified mice and validating drug targets
• VelociMab — automated high-throughput antibody screening and optimization
• Competitive moat — VelociSuite enables Regeneron to move from target identification to clinical candidate faster than most competitors. The platform has produced all of Regeneron's approved antibody medicines.
• Platform breadth — beyond monoclonal antibodies, Regeneron applies the platform to bispecific antibodies, gene therapy vectors, and other modalities

Capital Allocation

• New dividend — Regeneron initiated its first-ever quarterly dividend in 2025, signaling confidence in sustainable cash generation
• Share buybacks — increased total repurchase capacity to ~$4.5 billion. Active buyback program.
• R&D investment — substantial R&D spend (~$4.4B in FY2024, ~30% of revenue). Among the highest absolute R&D budgets in biotech.
• Manufacturing investment — announced >$7 billion in planned U.S. infrastructure investments (New York and North Carolina) plus $3B agreement with FUJIFILM Diosynth Biotechnologies
• Balance sheet — strong cash position. Net income ~$4.4B in FY2024.
• M&A approach — selective acquisitions (2seventy bio cell therapy pipeline in 2024). Generally prefers internal R&D over large M&A.

Key Risks

• EYLEA biosimilar erosion — legacy EYLEA faces multiple biosimilar competitors. Total EYLEA franchise revenue declining. EYLEA HD must capture enough share to stabilize the franchise, but the transition is not guaranteed.
• Dupixent collaboration dependency — Dupixent is Regeneron's largest profit contributor but is recorded/commercialized by Sanofi. Regeneron depends on Sanofi's commercial execution and the collaboration agreement terms.
• Revenue concentration — two franchises (EYLEA + Dupixent collaboration profits) represent the vast majority of Regeneron's economics. Pipeline diversification is critical.
• Pipeline execution risk — obesity, gene therapy, and bispecific programs are early/mid-stage. Clinical failures would limit growth beyond current franchises.
• Competitive pressure in immunology — other IL-4/IL-13 and IL-13-only antibodies in development could challenge Dupixent's dominance in some indications.
• Pricing and access — EYLEA and Dupixent are expensive specialty medicines. Government pricing negotiations (IRA), payer pushback, and international reference pricing are ongoing risks.
• Ophthalmology market dynamics — Roche's Vabysmo (faricimab) is a bispecific antibody competitor gaining share in retinal diseases, adding pressure beyond biosimilars.
• Manufacturing complexity — biologics manufacturing is complex. Supply disruptions or quality issues could impact product availability.

Investor-Education Context

• Platform company — Regeneron's VelociSuite gives it a structural advantage in antibody drug discovery. The platform has produced multiple blockbuster medicines across unrelated therapeutic areas, demonstrating repeatability.
• Collaboration model — the Sanofi partnership for Dupixent means Regeneron captures ~50% of the world's largest immunology drug's profits without bearing 100% of commercial costs. This is capital-efficient but creates dependency.
• Transition period — Regeneron is navigating the EYLEA-to-EYLEA HD transition while biosimilars erode the legacy product. The company's ability to retain ophthalmology patients on EYLEA HD is a key near-term question.
• Science-driven culture — Regeneron is led by its co-founders (Schleifer as CEO, Yancopoulos as CSO) after 35+ years. The company prioritizes internal R&D over acquisitions, which creates both pipeline depth and execution risk.
• Diversification imperative — with EYLEA under pressure and Dupixent eventually facing its own patent expiry, Regeneron must successfully commercialize pipeline programs (obesity, oncology, gene therapy) to sustain long-term growth.

This article is educational. It does not constitute investment advice, a recommendation to buy or sell, or a valuation opinion.

Sources

• Regeneron Pharmaceuticals 10-K FY2024 (SEC EDGAR, CIK 0000872589)
• Regeneron FY2024 Full Year Earnings Release — total revenue $14.20 billion, initiated quarterly dividend
• Regeneron FY2025 Full Year Earnings Release (Jan 30, 2026) — total revenue $14.3 billion, Dupixent global net sales $17.8B
• Regeneron Q1 2025 Earnings Release — Dupixent $3.67B quarterly, EYLEA HD $307M
• Regeneron Q3 2025 Earnings Release — Dupixent $4.86B quarterly, Libtayo 26% growth
• FDA approvals: EYLEA HD for RVO and monthly dosing (2025), Libtayo adjuvant CSCC (2025)
• Sanofi collaboration disclosures for Dupixent global net sales